Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is having an incredibly strong start to the trading session this morning afte rthe company announced a poster presentation and clinical data. Of course, the news excited investors, sending the stock screaming for the top. Today, we’ll talk about:
- The poster presentation;
- what we’re seeing from TNXP as a result; and
- what we’ll be watching for ahead.
TNXP Climbs On Poster Presentation
As mentioned above, Tonix Pharmaceuticals is having an incredibly strong start to the trading session this morning after the company announced a poster presentation. In a press release issued early this morning, the company said that it will be presenting a poster today at the 2018 Military Health System Research Symposium in Kissemmee. The poster is titled “Effect of Time Since Trauma on Response to TNX-102 SL”.
In the release, TNXP said that the poster includes results fo two double-blind clinical trials and a retrospective analysis. The trials include the Phase 3 P301 study and the Phase 2 P201 study. During these studies, the company assessed TNX-102 as a treatemt for posttraumatic stress disorder.
In a statement, Dr. Seth Lederman, CEO at TNXP, had the following to offer:
The P301 and P201 studies help to advance the clinical development of TNX-102 SL for PTSD. Future studies will focus on patients with more recent trauma (less than nine years). The finding that treatment response to Tonmya in P301 decreases as the time since trauma gets longer, suggests that military service members and veterans with PTSD are transitioning from a Tonmya-treatment responsive state to a non-responsive state after approximately nine years. These results emphasize the urgency for early diagnosis and treatment for PTSD, especially for military-related PTSD.
The above statement was followed up by Dr. Gregory Sullivan, CMO at TNXP. Here’s what he had to offer:
Trauma is the cause of PTSD, but PTSD is a complex condition with clear evidence of a dynamic pathophysiology which changes over time. Treatment responsiveness over the course of the disease may vary with different pharmacological classes, and may also differ between PTSD from combat versus other types of trauma. Yet it is unclear what specific features of PTSD change over time and make it less treatment responsive. These findings of P301 and P201 show that in PTSD, time since trauma is important in the treatment response to Tonmya. Other aspects of PTSD have been observed to depend on time since trauma, such as a decrease in the rates of remission the more years out from the trauma.1 The subgroup with trauma less than nine years prior to screening in P301 may include more participants within the ‘remitting’ phase of PTSD, while the greater than nine years since trauma subgroup in P301 may include more participants in the ‘persistent’ phase of PTSD, which have been described in longitudinal studies of PTSD in the literature.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of Tonix Pharmaceuticals, the news proved to be overwhelmingly positive. After all, positive data is always a good thing. So, it comes as no surprise to see that excited investors are pushing the stock toward the top in the market today. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:13), TNXP is trading at $1.53 per share after a gain of $0.28 per share or 22.40% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on TNXP. In particular, we’re interested in following the company’s work in the PTSD space. Nonetheless, we’ll keep our eyes on the news and bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!